{"entity":{"id":"can020","kind":"drug","name":"CAN020","aka":[],"tldr":"CAN020 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.","summary":"AACR Drug Discovery and Development 2026 abstract A014 describes CAN020 with TOP1 and PARP inhibitor payloads. Cell and xenograft findings support a DNA-damage and repair-inhibition strategy. Breast, ovarian and gastric tumor models were tested. The authors propose advancement to phase I; that proposal is not evidence of trial initiation or human benefit.","status":"preclinical","asOf":"2026-10-06","links":[{"label":"Publisher abstract","url":"https://doi.org/10.1158/1557-3265.d32026-a014"}],"tags":["evidence:preclinical"],"related":[],"cancers":[],"sections":[],"technologies":["adc","dual-payload-adc"],"targets":["trop2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"ADC","payload":"TOP1 inhibitor plus PARP inhibitor","mechanism":"TROP2-directed ADC carrying a topoisomerase I inhibitor and a PARP inhibitor on a cleavable StarLinker platform.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/can020/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}]}}